Calgary, Alberta — December 23, 2025 — Leads & Copy — Hemostemix Inc. has announced the appointment of Dr. David B. Alper to a lead role as Multidisciplinary Physician Education Lead, and to its Scientific Advisory Board (SAB), effective January 2026.
Dr. Alper, a Doctor of Podiatric Medicine, will collaborate with Hemostemix on physician-led education and clinical engagement initiatives, focusing on wound-care podiatrists and multidisciplinary limb-preservation teams, starting in Florida.
Dr. Alper will assist Hemostemix in executing three parallel initiatives. The first is Clinical Practice Engagement in Florida. Dr. Alper will engage with wound-care podiatry practitioners and multidisciplinary limb salvage teams in Florida, to detail how VesCell (ACP-01) addresses pain and the ischemia-root-cause of peripheral arterial disease, diabetic foot ulcers, and amputation. This effort is designed to support increased use of ACP-01 in each medical practice, following responsible clinical education and data-informed practice development.
The second initiative is Schools of Podiatric Medicine. Dr. Alper will engage Deans of Clinical Education at U.S. schools of podiatry medicine, introducing graduating doctors of podiatry, and faculty, on ACP-01 intervention.
The third initiative is Multidisciplinary Education & Professional Forums. Dr. Alper will support Hemostemix’s participation in multidisciplinary educational forums involving podiatrists, vascular specialists, interventional physicians, nurses, and wound-care professionals. Content will focus on ischemic disease phenotyping, patient selection, procedural considerations, and ACP-01’s integration into real-world team-based practices.
Dr. Alper is a nationally recognized podiatry physician and leader in wound care, limb preservation, and diabetic foot management. He currently serves as a Trustee of the American Podiatric Medical Association, is a Fellow of the Royal College of Physicians and Surgeons of Glasgow, and has held numerous leadership and advisory roles across national wound-care, diabetes, and amputation-prevention organizations.
He is an inductee of the Hall of Fame, Kent State University College of Podiatry Medicine; serves as an Adjunct Professor in clinical education; serves as Emeritus Surgical staff at Mt. Auburn Hospital; is a member of the Leadership Board of the American Diabetes Association (ADA), New England, where he served as President for over 20 years; is an elected member of the Board of Trustees of the American Podiatry Medical Association (APMA); served as Chair of the Belmont (MA) Board of Health for 30 years; and, he currently sits on the Massachusetts Association of Health Boards (MAHB).
A noted speaker, published writer, and podcaster on a variety of podiatry topics including articles published in Prevention, Health Journal, and Walking magazines, Dr. Alper has focused on limb amputation prevention, forming collaborations between medical societies in the Diabetes, Podiatry and Vascular industries. He currently serves on the Boards of the Wound Care Collaborative Community (WCCC), the Alliance for Woundcare Stakeholders, the Foot Ankle Health section of the American Public Health Assn.; is co-chair of Professional and Public Education Committee for the PAD Collaborative; is a Board member of the Medical Advisory Panel of the Amputation Prevention Alliance; and, is a member of the Professional Communications Committee of the CLI Global Association.
According to Thomas Smeenk, CEO, welcoming Dr. Alper to lead ACP-01 physician education in the USA is an incredible honor. He said that Dr. Alper’s message to his colleagues is that the scientific evidence of ACP-01 justifies the clinical know-how to change the trajectory of these diseases, and that saving a limb is saving a life.
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. The company has developed, patented, is scaling and selling autologous blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina.
Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result.
For further information, please contact: Thomas Smeenk, President, CEO EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Source: Hemostemix Inc.
